Olmesartan Medoxomilo + Hidroclorotiazida Krka (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmesartan Medoxomilo + Hidroclorotiazida Krka, is an angiotensin II receptor blocker presented as a combined tablet for oral use. It treats hypertension in adults, often together with the thiazide diuretic component. GNH USA supplies Olmesartan Medoxomilo + Hidroclorotiazida Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxomil/hydrochlorothiazide is used to manage high blood pressure, a key factor in cardiovascular disease. - Hypertension: lowers systolic and diastolic pressure, reducing the risk of stroke and heart attack. - Essential hypertension: provides sustained blood‑pressure control when monotherapy is insufficient. - Secondary hypertension: assists in blood‑pressure reduction when caused by renal or endocrine disorders.

Common Side Effects: - Dizziness: transient light‑headedness, especially after the first doses. - Headache: mild to moderate intensity, often resolves with continued therapy. - Fatigue: general tiredness without specific cause. - Increased urination: due to the diuretic component. - Electrolyte imbalance: mild changes in potassium or sodium levels. - Mild gastrointestinal discomfort: nausea or abdominal cramps.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Acute kidney injury: sudden reduction in renal function. - Hyperkalemia: elevated potassium that may affect heart rhythm. - Hyponatremia: low sodium concentration, especially in elderly. - Allergic reactions: rash, itching, or angioedema. - Pancreatitis: rare inflammation of the pancreas.

Before initiating therapy, consider the following precautions: - Blood pressure monitoring: ensure target levels are achieved and maintained. - Renal function assessment: evaluate serum creatinine and eGFR regularly. - Electrolyte surveillance: check potassium and sodium levels, especially with concomitant diuretics. - Hepatic impairment: use with caution in patients with severe liver disease. - Pregnancy and lactation: avoid use unless clearly indicated, as safety data are limited. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan medoxomil/hydrochlorothiazide may interact with several medicines. Major Interactions (Avoid): - Aliskiren (in diabetic patients): risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Lithium: increased lithium levels leading to toxicity. Moderate Interactions (Monitor Closely): - NSAIDs: can blunt antihypertensive effect and affect renal function. - Antidiabetic agents: may require dose adjustment due to enhanced glucose‑lowering effect. - CYP450 inhibitors (e.g., fluconazole): may increase olmesartan plasma concentrations.